Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Invested Capital (2016 - 2025)

Plus Therapeutics has reported Invested Capital over the past 16 years, most recently at $4.7 million for Q4 2025.

  • Quarterly Invested Capital rose 183.9% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 183.9% year-over-year, with the annual reading at $4.7 million for FY2025, 183.9% up from the prior year.
  • Invested Capital was $4.7 million for Q4 2025 at Plus Therapeutics, down from $5.1 million in the prior quarter.
  • Over five years, Invested Capital peaked at $21.5 million in Q3 2021 and troughed at -$23.6 million in Q1 2025.
  • The 5-year median for Invested Capital is $7.2 million (2023), against an average of $5.9 million.
  • The largest YoY upside for Invested Capital was 368.54% in 2025 against a maximum downside of 1795.83% in 2025.
  • A 5-year view of Invested Capital shows it stood at $12.4 million in 2021, then tumbled by 35.29% to $8.1 million in 2022, then plummeted by 67.37% to $2.6 million in 2023, then crashed by 315.26% to -$5.7 million in 2024, then soared by 183.9% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Invested Capital are $4.7 million (Q4 2025), $5.1 million (Q3 2025), and $3.0 million (Q2 2025).